Clinical Trials Logo

Scopolamine clinical trials

View clinical trials related to Scopolamine.

Filter by:
  • None
  • Page 1

NCT ID: NCT04999449 Recruiting - Motion Sickness Clinical Trials

Nebulizer Delivery of Intranasal Scopolamine

Start date: January 24, 2022
Phase: Phase 1
Study type: Interventional

To develop a better way to administer anti-motion sickness medications using an intranasal nebulizer.

NCT ID: NCT04391361 Not yet recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS

Start date: November 1, 2020
Phase: Phase 2
Study type: Interventional

Thirty cases of amyotrophic lateral sclerosis patients were recruited from the neurology department of Ruijin Hospital, the pain department and the encephalopathy center of Luwan Branch of Ruijin Hospital. After the informed consent was signed, they were divided into a trial group and a control group. Each group contains 15 cases. The patients in the control group was treated with edaravone dissolved in saline during hospitalization, while the patients in the trial group was treated with edaravone, scopolamine, atropine and dexmedetomidine. Both groups of subjects were treated for 7 days within 3 weeks, followed by a buffer period of 3 weeks for observation, which was one treatment course. The total treatment protocol contains 3 treatment courses (or 18 weeks). Patients with amyotrophic lateral sclerosis were evaluated before treatment and 6, 12, 18, 24, 36, 48 weeks after treatment. The observations include whether the functional scores of patients with amyotrophic lateral sclerosis, Norris amyotrophic lateral sclerosis score, amyotrophic lateral sclerosis self-score, forced expiratory volume in one second, partial pressure of oxygen and maximum displacement of the hyoid were superior to those before treatment, and whether the partial pressure of carbon dioxide was inferior to those before treatment. Study hypothesis: Cholinergic receptor blocking therapy for amyotrophic lateral sclerosis is safe and effective in improving motor function and delaying disease progression in patients with amyotrophic lateral sclerosis.